dc.contributor.author
Beyer, Katharina
dc.contributor.author
Baukloh, Ann-Kathrin
dc.contributor.author
Stoyanova, Ani
dc.contributor.author
Kamphues, Carsten
dc.contributor.author
Sattler, Arne
dc.contributor.author
Kotsch, Katja
dc.date.accessioned
2020-02-28T09:16:16Z
dc.date.available
2020-02-28T09:16:16Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/26772
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-26529
dc.description.abstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily. TRAIL has historically been distinct from the Fas ligand and TNFα in terms of selective apoptosis induction in tumor cells and has a nearly non-existent systemic toxicity. Consequently, in the search for an ideal drug for tumor therapy, TRAIL rapidly drew interest, promising effective tumor control with minimal side effects. However, euphoria gave way to disillusionment as it turned out that carcinoma cells possess or can acquire resistance to TRAIL-induced apoptosis. Additionally, studies on models of inflammation and autoimmunity revealed that TRAIL can influence immune cells in many different ways. While TRAIL was initially found to be an important player in tumor defense by natural killer cells or cytotoxic T cells, additional effects of TRAIL on regulatory T cells and effector T cells, as well as on neutrophilic granulocytes and antigen-presenting cells, became focuses of interest. The tumor-promoting effects of these interactions become particularly important for consideration in cases where tumors are resistant to TRAIL-induced apoptosis. Consequently, murine models have shown that TRAIL can impair the tumor microenvironment toward a more immunosuppressive type, thereby promoting tumor growth. This review summarizes the current state of knowledge on TRAIL’s interactions with the immune system in the context of cancer.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
inflammation
en
dc.subject
immune system
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Interactions of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) with the Immune System: Implications for Inflammation and Cancer
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
1161
dcterms.bibliographicCitation.doi
10.3390/cancers11081161
dcterms.bibliographicCitation.journaltitle
Cancers
dcterms.bibliographicCitation.number
8
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
11
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
31412671
dcterms.isPartOf.eissn
2072-6694